Helle
Helle Bielefeldt-Ohmann, Queensland AU
Patent application number | Description | Published |
---|---|---|
20100112004 | HYPOXIA INDUCIBLE FACTOR INDUCER AND METHODS FOR USING THE SAME - The present invention provides vaccine compositions and methods for using the same. Generally, the vaccine is used to prevent infection of a microorganism that produces an HIF inducing compound. Accordingly, vaccines of the invention comprise at least a portion of an HIF inducing compound that is produced by the microorganism. | 05-06-2010 |
Helle Demuth, Rungsted Kyst DK
Patent application number | Description | Published |
---|---|---|
20110306548 | STABLE GROWTH HORMONE COMPOUNDS - The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation. | 12-15-2011 |
20130040883 | STABLE GROWTH HORMONE COMPOUNDS - The present invention relates to growth hormone (GH) compounds having additional disulphide bridges and at least one additional single point mutation making the compounds resistant to proteolytic degradation. | 02-14-2013 |
20130143815 | GROWTH HORMONE CONJUGATES - The present invention relates to growth hormone conjugates comprising a bile acid residue, said conjugation may occur through wt or mutant amino acid residues. The growth hormone polypeptide may be wt human growth hormone or a growth hormone variant. | 06-06-2013 |
Helle Funch Nielsen, Hoersholm DK
Patent application number | Description | Published |
---|---|---|
20110214671 | INHALER ASSEMBLY - The present invention provides an inhaler assembly for providing medications in aerosol form to animals, especially equines. The inhaler assembly comprises a holder adapted to retain at least two diffusion canisters containing either substantially the same or different drug formulations. The canister holder has an outlet in communication with the inlet of a spacer. The spacer, in turn, has an outlet in communication with a mask such that, in use, medication from at least one of the canisters can be dispensed into the spacer for inhalation in aerosol form via the mask. | 09-08-2011 |
Helle Haraldsted, Glostrup DK
Patent application number | Description | Published |
---|---|---|
20140194841 | Catheter Activation by Handle Removal - The invention relates to a catheter kit comprising a catheter and a urine bag stored in a package wherein flow is prevented between the catheter and urine bag when stored but enabled when the kit is used. | 07-10-2014 |
Helle Jensen, Silkeborg DK
Patent application number | Description | Published |
---|---|---|
20140242585 | Genetic Test for the Identification of Carriers of Complex Vertebral Malformations in Cattle - Genetic markers for identifying bovine carriers of complex vertebral malformation (CVM) disease gene are described. The genetic markers, including the microsatellite markers BM4129, INRAA003, BMS2790, ILSTS029, INRA123, BM220, HUJ246, BMS862, BMS937, BL1048, BMS2095 and BMS1266 and the bovine SLC35A3 gene, are located on bovine chromosome BTA3. The G/T polymorphism at position 559 of the bovine SLC35A3 gene is identified as being causative and diagnostic for CVM in cattle. | 08-28-2014 |
Helle KayerØd, Nærum DK
Patent application number | Description | Published |
---|---|---|
20100306893 | PROTECTIVE FACE MASK - A protective face mask includes an eye-protecting shield made essentially from a plastics material. The eye-protecting shield is dimensioned to cover at least the eye portions of a human wearer. The eye-protecting shield has a perimeter defining a first surface facing the wearer's face, and a second surface facing away from the wearer's face. An adhesive forms an adhesive strip attached to the first surface of the eye-protecting shield for providing a substantially watertight and releasable sealing engagement between at least a portion of the perimeter forming an upper edge of the face mask and at least a portion of the skin of the wearer's face. | 12-09-2010 |
Helle Kuura, Tartu EE
Patent application number | Description | Published |
---|---|---|
20090117094 | Method Of Making The Porous Carbon Material And Porous Carbon Materials Produced By The Method - A method for making the microporous carbon with modified pore size distribution and advanced sorption behaviour. The carbon is derived from metal or metalloid carbides. The method employs the use of oxidant in reaction medium that during the carbide conversion into carbon widens small micropores, which otherwise would be hardly accessed by sorbing molecules or ions in practical applications. The microporous carbon obtained is free of impurities and possesses extremely narrow pore size distribution. | 05-07-2009 |
Helle Lysdahl, Mårslet DK
Patent application number | Description | Published |
---|---|---|
20140350680 | PROCESS FOR MODIFYING THE SURFACE MORPHOLOGY OF A MEDICAL DEVICE - The present invention relates to a process for modifying the surface morphology of a medical device. The modified surface has, among other advantageous properties, an improved capacity for sorption or conjugation of a variety of bioactive agents, the addition of which will turn the medical device into a localized drug delivery system. | 11-27-2014 |
Helle Naver, Allerod DK
Patent application number | Description | Published |
---|---|---|
20090069216 | Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof - The present invention is related to fast acting single-chain insulin comprising a modified B-chain and the A-chain of human insulin or an analogue thereof connected by a connecting peptide wherein one or more of the amino acid residues in position B25, B26 or B27 in the human B-chain are Glu or Asp or are deleted and/or B28 is Glu, Asp, Lys or is deleted, and the amino acid residue in position B10 in the human insulin B-chain is Gln, Ala, Val, Thr or Ser. The invention is also related to pharmaceutical compositions being a mixture of the rapid acting single-chain insulin and the protracted acylated insulin. | 03-12-2009 |
20110009314 | Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof - The present invention is related to fast acting single-chain insulin comprising a modified B-chain and the A-chain of human insulin or an analogue thereof connected by a connecting peptide wherein one or more of the amino acid residues in position B25, B26 or B27 in the human B-chain are Glu or Asp or are deleted and/or B28 is Glu, Asp, Lys or is deleted, and the amino acid residue in position B10 in the human insulin B-chain is Gln, Ala, Val, Thr or Ser. The invention is also related to pharmaceutical compositions being a mixture of the rapid acting single-chain insulin and the protracted acylated insulin. | 01-13-2011 |
Helle Naver, Bagsvaerd DK
Patent application number | Description | Published |
---|---|---|
20120135920 | Preparation Comprising Insulin, Nicotinamide and an Amino Acid - Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid. | 05-31-2012 |
20130281364 | Preparation Comprising Insulin, Nicotinamide and an Amino Acid - Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid. | 10-24-2013 |
Helle Naver, Alleroed DK
Patent application number | Description | Published |
---|---|---|
20120196800 | STABLE NON-AQUEOUS LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING AN INSULIN - The invention describes a non-aqueous liquid pharmaceutical composition comprising at least one lipid and at least one insulin. Also described is a method of producing a pharmaceutical composition comprising a lipid and a method of purifying a lipid, a cosolvent, a surfactant or a pharmaceutical composition comprising a lipid. | 08-02-2012 |
20120245085 | Pharmaceutical Solution of Non Covalently Bound Albumin and Acylated Insulin - If albumin is added to a pharmaceutical formulation containing acylated insulin described in WO 2009/022005 and WO 2009/022013, the acylated insulin can be kept in solution after subcutaneous injection. | 09-27-2012 |
20140206610 | Preparation Comprising Insulin, Nicotinamide and an Amino Acid - Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid. | 07-24-2014 |
20140329744 | STABLE NON-AQUEOUS LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING AN INSULIN - The invention describes a non-aqueous liquid pharmaceutical composition comprising at least one lipid and at least one insulin. Also described is a method of producing a pharmaceutical composition comprising a lipid and a method of purifying a lipid, a cosolvent, a surfactant or a pharmaceutical composition comprising a lipid. | 11-06-2014 |
20150111820 | NOVEL USE OF INSULIN DERIVATIVES - This invention relates to insulin derivatives having long duration of action. The insulin derivatives have been found to be useful for the treatment of diabetes, and in particular for less frequent administration to the diabetic patients, in particular as seldom as about once weekly. | 04-23-2015 |
20150126442 | INSULIN FORMULATIONS - A stable pharmaceutical formulation containing an insulin derivative can conveniently be prepared by adding glycerol, phenol, m-cresol and zinc ions to it. | 05-07-2015 |
20150182595 | Preparation Comprising Insulin, Nicotinamide and an Amino Acid - Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid. | 07-02-2015 |
Helle Sadam, Tallinn EE
Patent application number | Description | Published |
---|---|---|
20080206770 | SCREENING METHODS USED TO IDENTIFY COMPOUNDS THAT MODULATE SKIN STROMAL CELLS (FIBROBLASTS) ABILITY TO MODIFY FUNCTION OF EXTRACELLULAR MATRIX - The cellular response to cosmetic products has been characterized on the molecular level through the use of gene and protein expression technologies. Nucleic acid and protein molecules, the expression of which are induced or repressed in response to exposure to cosmetics, are identified according to a temporal pattern of altered expression post exposure. Methods are disclosed that utilized these cosmetics-regulated molecules as markers for effectiveness of cosmetics. Other screening methods of the invention are designed for the identification of compounds that modulate the response of a cell to exposure to cosmetics. The invention also provides compositions useful for drug screening or pharmaceutical purposes. | 08-28-2008 |
Helle Ullerup, Eindhoven NL
Patent application number | Description | Published |
---|---|---|
20150297176 | ULTRASOUND HEAD FRAME FOR EMERGENCY MEDICAL SERVICES - A head frame is configured for the head of a medical patient ( | 10-22-2015 |
Helle Windfeld, Horning DK
Patent application number | Description | Published |
---|---|---|
20120160636 | ADJUSTABLE CONVEYOR EXTENSIONS - Example conveyor systems are disclosed herein. An example conveyor system includes a main conveyor with a frame supporting at least one conveyor extension. Some conveyor extension examples include a powered conveyor belt supported by one or more conveyor sections that are articulated for assisting one or more workers in transferring items (e.g., boxes, parcels, luggage, parts, etc.) to and from the main conveyor. A single main conveyor supports two conveyor extensions mounted alongside each other with someone working at each extension to allow two workers to service a single main conveyor with minimal or no interference, thereby increasing the conveyor system's overall transfer rate. Example conveyor system disclosed herein includes various elements of positional adjustment (e.g., lateral, longitudinal, vertical, angular) to make the conveyor system particularly suited for transferring parcels between a loading dock and the interior of a truck, trailer, aircraft or container. | 06-28-2012 |
Helle Woeldike, Lynge DK
Patent application number | Description | Published |
---|---|---|
20130252884 | FGF21 ANALOGUES AND DERIVATIVES - Novel analogues of Fibroblast Growth Factor 21 (FGF21), derivatives thereof having a modifying moiety covalently attached thereto, and pharmaceutical use of these analogues and derivatives, in particular, for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD) are described. | 09-26-2013 |
Helle Wöldike, Lynge DK
Patent application number | Description | Published |
---|---|---|
20100216715 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use - The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability. | 08-26-2010 |
20120035099 | FGF21 ANALOGUES AND DERIVATIVES - Derivatives of Fibroblast Growth Factor 21 which have improved properties for treating diabetes can be prepared by a recombinant process. | 02-09-2012 |
Helle Wöldike, Lynge DK
Patent application number | Description | Published |
---|---|---|
20090035821 | Expression of Proteins in E.Coli - Plasmid comprising a DNA tag encoding a peptide tag of the sequence MX | 02-05-2009 |
20090253864 | IL-21 Derivatives and Variants - The invention provides derivatives of IL-21 or variants thereof, methods of producing such variants, new variants of IL-21, and various methods of using such molecules. | 10-08-2009 |
20100041153 | Expression of Proteins in E. Coli - Plasmid comprising a DNA tag encoding a peptide tag of the sequence MX1(X 2X 3) n X 1 represents K or R; X 2 represents M, S or T; X 3 represents K or R; n represents an integer of 1 or larger; and wherein said DNA is operably-linked to a promoter sequence are provided. | 02-18-2010 |
20100216715 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use - The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability. | 08-26-2010 |